The top listed Chinese healthcare and life sciences companies have had a strong run on the stock market over the recent past, including during the COVID-19 outbreak, with price-to-earnings (PE) multiples dwarfing peers in markets like India and Japan and even ahead of US big pharma in some instances.
APAC Life Sciences Valuation Trends: Chinese Firms Eclipse Japan, India Peers
Emerging Innovation Driving Values?
Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.
More from Business
• By
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.
• By
The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.
• By
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
More from Scrip
• By
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.